Fri, Nov 21, 2014, 2:30 PM EST - U.S. Markets close in 1 hr 30 mins

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • johnpapas893 johnpapas893 Oct 11, 2012 8:05 PM Flag

    Questions relayed by Feuerstein

    What are your impressions of Dr Boyle's presentation and the investor conference? The questions relayed by Feuerstein were answered--right?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The elephant in the room is sweat chloride, which was an original study endpoint. Had they been able to give a logical explanation for the lack of reduction in sweat chloride AND shown the FEV improvement they have shown then the skeptics would be converted.

      • 1 Reply to crossroads4040
      • Biology doesn't always follow the timeline of an experimental hypothesis. Anecdotal reports by patients with non G551 gating mutations receiving Kalyedco are demonstrating early improvements in FEV-1 just like in this study, with sweat chloride slowing improving subsequently over the first three months of treatment. The theory that sweat chlorides have to be linearly improving at the same pace (or sooner) than improvements in pulmonary function were not correct assumptions as evident in homozygous 508 CF patients, as well as the non-551 gating patients reporting pulmonary function and subjective symptoms improvement before seeing sweat chlorides dropping so far. The most important point is that the results are statistically significant in the treatment group using 809 with Kalydeco and that FEV-1 and not sweat chloride, is the end point that the FDA will use to judge the efficacy of these drugs.

        Sentiment: Strong Buy

 
VRTX
112.38-0.51(-0.45%)2:29 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.